Objective To discuss the potential relationship between endometrial serous carcinoma (ESC) and tubal epithelial lesions by pathologic examination of fallopian tubes with ESC. Methods A total of 30 cases of typical ESC were reexamined and chosen by the pathologist. In each case, bilateral fallopian tubes were submitted to examination of pathologic morphology and immunostaining for p53, annexin Ⅳ(ANX-Ⅳ), human epidermal growth factor receptor 2(HER2)/neu, and high-mobility group protein A2 (HMGA2). Results Fallopian tubal epithelial lesions were found in 15 cases, including 9 cases tubal serous carcinoma, 2 cases serous tubal intraepithelial carcinoma (STIC) and 2 cases epithelial hyperplasia. Both sides of tubal serous carcinoma and STIC were found in 1 case. The results showed the positive expression for p53 in 26(87%)out of 30 endometrial malignant specimens tissues and 9(30%)tubal tissues samples (P>0.05). Twenty-five(83%)endometrial malignant specimens tissues and 6(20%)tubal tissues samples showed the positive expression of ANX-Ⅳ. Twenty-one(70%)endometrial malignant tissues and 7(23%) tubal tissues showed the positive expression of HER2/neu. Twenty-five(83%) endometrial malignant tissues and 6(20%)tubal tissues showed the positive expression of HMGA2. While, there were significant differences among the expression of three proteins between endometrium and the fallopian tube site (all P<0.05). Conclusions STIC may be associated with the occurrence of ESC. The expression of p53 was positively correlated between the fallopian tube and the endometrium. ANX-Ⅳ,HER2/neu and HMGA2 were extensively expressed in ESC.

Objective To explore the lymph nodes (LN) metastasis characters of the endometrial carcinoma and its relation with the patients' prognosis. Methods A retrospective study was carried out on 227 cases of endometrial carcinoma who admitted to our department and underwent LN excision from Jul. 2000 to Feb. 2008. Results Among 227 cases who underwent pelvic LN excision, there were 22 cases (9.7%) presented LN metastasis. There were 12 cases with positive external iliac LN from 20 cases of patients with data in LN grouping. Para-aortic LN excision was carried out on 138 patients. There were 6 cases with positive para-aortic LN, 5 cases of them together with pelvic LN metastasis. Those patients with cervix involvement, annex metastasis, deep myometrium infiltration, grade 2-3 and negative estrogen receptor occurred pelvic LN metastasis more frequently than the others ( P ＜ 0. 05 ). Among the 6 cases with positive para-aortic LN, there were 3 cases ( 3/6) with deep myometrium infiltration. For those whose paraaortic LN was negative, it was only 16. 7% (22 cases). But there were no difference statistically between them ( P＞ 0. 05 ). There were significant difference in 3 years disease-free survival rate between patients with positive pelvic LN or negative pelvic LN [(81. 8 ± 8. 2)% vs ( 97. 4 ± 1. 2 ) % , P = 0. 004]. While there were not significant difference in 3 years disease-free survival rate between patients with positive para-aortic LN or negative para-aortic LN [100% vs ( 96. 7 ± 1. 6) % , P ＞ 0. 05]. Single factor analysis showed that the age more than 50 years, annex metastasis and pelvic LN metastasis related with the recurrence (P ＜0. 01). But cervix involvement, deep myometrium infiltration, para-aortic LN metastasis, pathology type, tumor grade and estrogen receptor did not relate with the recurrence ( P ＞ 0. 05 ). Cox regression analysis showed that annex metastasis and the age of patients were independent risk factors affecting the recurrence ( P = 0. 011, P = 0. 025 ). Conclusions The most common site of pelvic LN metastasis is the external iliac LN for endometrial carcinoma patients. The patients with positive para-aortic LN always accompanied pelvic LN metastasis. Those patients with cervical involvement, annex metastasis, deep myometrium infiltration, poor differentiation and negative estrogen receptor be more likely exist pelvic LN metastasis. Pelvic LN metastasis may affect the prognosis of endometrial carcinoma patients.

Objective To explore the impact of 2009 International Federation of Gynecology and Obstetrics(FIGO)staging system alteration for stage Ⅰ endometrioid adenocarcinoma on its' prognosis assessing.Methods A retrospective study was carried out on 244 cases with endometrial carcinoma admitted in Peking University People's Hospital from Jan.1995 to Feb.2008.Results(1)All 244 patients were divided into FIGO 2009 Ⅰ a group(n =200)and FIGO 2009 Ⅰ b group(n =44)according to FIGO 2009 staging system,while they were divided into FIGO 1988 Ⅰ a group(n =34),FIGO 1988 Ⅰ b group(n =156)and FIGO 1988 Ⅰ c group(n =29).The others 25 cases were stage Ⅱ a(n =16)and stage Ⅲa with merely positive abdominal cytology(n =9)according to FIGO 1988 staging system.(2)The higher percentage of low-grade in FIGO 1988 Ⅰ a group than that in FIGO 2009 Ⅰ a group(P =0.003).Compared with FIGO 2009 Ⅰ a group,the age of the patients,surgery extent,the percentage of lymph node excision and received chemotherapy and radiotherapy,there were no difference in FIGO 1988 Ⅰ a and Ⅰ b group,respectively(P ＞ 0.05).There were 5.9％(2/34)and 6.7％(10/150)found relapse among FIGO 1988 Ⅰ a group and FIGO 1988 Ⅰ b group,and there were 2.9％(1/34)and 2.7％(4/150)for the two groups died of carcinoma.Compared with FIGO 2009 Ⅰ a group,there were not significant difference[7.5％(13/200)vs.3.0％(6/200);P ＞0.05].The 5 years and 10 years progression-free survival(PFS)of FIGO 1988 Ⅰ a group and Ⅰ b group were(97.0 ±3.0)％,(90.9 ±6.5)％ and(95.3 ±2.1)％,(90.2 ± 3.6)％,respectively,in which there were not significant difference compared with that in FIGO 2009 Ⅰ a group[(96.1 ±1.6)％,(89.6±3.2)％ ; P＞0.05].The 5 years and 10 years overall survival(OS)in FIGO 1988 Ⅰ a group and Ⅰ b group were 100％,(93.8 ±6.0)％ and(96.9 ± 1.8)％,(95.2 ±2.5)％,respectively,in which there were did not significant difference with that in FIGO 2009 Ⅰ a group [(97.9 ± 1.2)％,(93.4 ± 2.8)％ ; P ＞ 0.05].(3)There were not significant difference between FIGO 1988 Ⅰ c group and FIGO 2009 Ⅰ b group(P ＞0.05)for the age of the patients,grade,surgery extent,lymph node excision,the percentage of received chemotherapy and radiotherapy.Between FIGO 1988 Ⅰ c group and FIGO 2009 Ⅰ b group,there were 3.4％(1/29)and 6.8％(3/44)cases found relapse,respectively.And there were 0 and 2.3％(1/44)cases died of carcinoma in the two groups,in which there were not differ much either(P ＞ O.05).The 5 years and 10 years PFS in FIGO 1988 Ⅰ c group were all 100％,while they were 100％ and(90.9 ±6.2)％ in FIGO 2009 Ⅰ b group.The 5 years and 10 years OS in FIGO 1988 Ⅰ c group were all 100％,but were 100％ and(95.0 ±4.9)％ in FIGO 2009 Ⅰ b group,in which they all did not significantly differ much(P ＞ 0.05).(4)The patients in FIGO 2009 Ⅰ a group were younger than those in FIGO 2009 Ⅰ b group(P ＜ 0.01).The percentage of low grade in FIGO 2009 Ⅰ a group were higher than that in FIGO 2009 Ⅰ b group(P =0.029).The percentages of received chemotherapy and radiotherapy in FIGO 2009 Ⅰ a group were lower than that in FIGO 2009 Ⅰ b group remarkably(P ＜ 0.01).But there were not significant difference in the uterine excision extent and the percentage of lymph node excision between the two groups(P ＞ 0.05).There were not significantly differ in the relapse rates and the death rates between the FIGO 2009 Ⅰ a group and FIGO 2009 Ⅰ b group(P ＞0.05).There were also not significant difference in PFS and OS between the two groups(P ＞0.05).Conclusions There were not significant difference in the prognosis between FIGO 2009 stage Ⅰ a and FIGO 1988 stage Ⅰ a and Ⅰ b.There were also not significant difference in the prognosis between FIGO 2009 stage Ⅰ a and FIGO 2009 stage Ⅰ b,which may be due to received more chemotherapy and radiotherapy in FIGO 2009 stage Ⅰ b patients.